Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Read Why Valneva's Stock Gained 7% Today

  • Valneva SE (NASDAQ:VALNcompleted the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553.
  • Valneva posted topline results from the phase 3 trial in August last year. The primary endpoint result is mainly unchanged from that data drop. 
  • The removal of two subjects from the analysis increased the proportion of participants with protective neutralizing antibody titers from 98.5% to 98.9%, 28 days after receiving a single shot of VLA1553. 
  • Valneva now also has longer-term immunogenicity data. After six months, 96.3% of the analyzed subjects had protective levels of CHIKV neutralizing antibodies. 
  • The slight decline between the first and sixth months of the trial still leaves Valneva well above the 70% level of seroprotection it expects the FDA to use as a surrogate of protection.
  • Valneva plans to monitor the durability of the antibody response in a subset of participants for at least five years as part of a dedicated persistence trial. 
  • With topline lot-to-lot manufacturing consistency results for VLA1553 due in Q2, Valneva is now close to gathering the evidence it will need to file for approval in the U.S.
  • The plan is to start the pre-submission process with the FDA in the second quarter. 
  • Suppose Valneva hits that target and avoids any regulatory setbacks. In that case, it should receive a priority review voucher for becoming the first company to win approval for a chikungunya vaccine in the U.S.
  • Price Action: VALN shares closed 7.40% at $29 on Tuesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.